Blue Trust Inc. Sells 645 Shares of McKesson Corporation $MCK

Blue Trust Inc. lessened its holdings in McKesson Corporation (NYSE:MCK) by 11.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,213 shares of the company’s stock after selling 645 shares during the quarter. Blue Trust Inc.’s holdings in McKesson were worth $4,276,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of MCK. Alliancebernstein L.P. raised its holdings in shares of McKesson by 150.4% during the 2nd quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after buying an additional 1,362,386 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in McKesson by 45.6% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock valued at $610,977,000 after buying an additional 261,296 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in McKesson by 34.1% in the second quarter. The Manufacturers Life Insurance Company now owns 839,690 shares of the company’s stock valued at $615,305,000 after buying an additional 213,406 shares in the last quarter. SurgoCap Partners LP grew its position in McKesson by 68.7% in the third quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock valued at $349,390,000 after acquiring an additional 184,106 shares during the last quarter. Finally, Danica Pension Livsforsikringsaktieselskab bought a new position in McKesson in the third quarter valued at about $135,352,000. Institutional investors own 85.07% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on MCK shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Leerink Partners reaffirmed an “outperform” rating and set a $1,085.00 price target on shares of McKesson in a report on Thursday, March 5th. JPMorgan Chase & Co. upped their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. TD Cowen increased their price objective on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $966.00 target price on shares of McKesson in a research note on Thursday, January 29th. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $960.93.

McKesson Stock Performance

Shares of NYSE MCK opened at $873.50 on Thursday. The company’s 50 day moving average price is $909.89 and its 200-day moving average price is $842.98. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00. The company has a market capitalization of $106.99 billion, a P/E ratio of 25.12, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. McKesson’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd were given a $0.82 dividend. The ex-dividend date of this dividend was Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,868 shares of company stock worth $3,743,820. Corporate insiders own 0.08% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.